相似文献
1
Molecular Aspects of Cardiometabolic Diseases: From Etiopathogenesis to Potential Therapeutic Targets.
Int J Mol Sci. 2024 May 27;25(11):5841. doi: 10.3390/ijms25115841.
2
Lactate-induced lactylation and cardiometabolic diseases: From epigenetic regulation to therapeutics.
Biochim Biophys Acta Mol Basis Dis. 2024 Aug;1870(6):167247. doi: 10.1016/j.bbadis.2024.167247. Epub 2024 May 16.
3
Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences.
Int J Mol Sci. 2020 Jan 13;21(2):494. doi: 10.3390/ijms21020494.
4
Laboratory assessment of cardiometabolic risk in overweight and obese children.
Clin Biochem. 2015 Apr;48(6):370-6. doi: 10.1016/j.clinbiochem.2014.12.024. Epub 2015 Jan 10.
5
American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome.
Endocr Pract. 2005 Mar-Apr;11(2):126-34. doi: 10.4158/EP.11.2.125.
6
[Correlation between insulin resistance and puberty in children with increased cardiometabolic risk].
Orv Hetil. 2011 Jul 3;152(27):1068-74. doi: 10.1556/OH.2011.29159.
7
Perinatal exposure to maternal obesity: Lasting cardiometabolic impact on offspring.
Prenat Diagn. 2020 Aug;40(9):1109-1125. doi: 10.1002/pd.5784. Epub 2020 Aug 5.
8
[The role of adipokines in formation of lipid and carbohydrate metabolic disorders in patients with cardiovascular disease].
Georgian Med News. 2012 Dec(213):26-31.
9
Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy.
Diabetes Care. 2014 Oct;37(10):2813-21. doi: 10.2337/dc14-0937. Epub 2014 Jul 10.
10
Overweight and obesity: the pathogenesis of cardiometabolic risk.
Clin Cornerstone. 2009;9(4):30-40; discussion 41-2. doi: 10.1016/s1098-3597(09)80003-3.
本文引用的文献
1
Cholesterol-Lowering Strategies for Cardiovascular Disease Prevention: The Importance of Intensive Treatment and the Simplification of Medical Therapy.
J Clin Med. 2024 Mar 25;13(7):1882. doi: 10.3390/jcm13071882.
2
The role of structured inpatient lipid protocols in optimizing non-statin lipid lowering therapy: a review and single-center experience.
Front Cardiovasc Med. 2024 Jan 25;11:1284562. doi: 10.3389/fcvm.2024.1284562. eCollection 2024.
3
Targeting gut microbiota in aging-related cardiovascular dysfunction: focus on the mechanisms.
Gut Microbes. 2023 Dec;15(2):2290331. doi: 10.1080/19490976.2023.2290331. Epub 2023 Dec 10.
4
Reply to Najjar, R.S. Comment on "Dyńka et al. The Ketogenic Diet and Cardiovascular Diseases. 2023, , 3368".
Nutrients. 2023 Oct 10;15(20):4312. doi: 10.3390/nu15204312.
5
Update on the Obesity Epidemic: After the Sudden Rise, Is the Upward Trajectory Beginning to Flatten?
Curr Obes Rep. 2023 Dec;12(4):514-527. doi: 10.1007/s13679-023-00527-y. Epub 2023 Oct 2.
6
Lifestyle or pharmacotherapy in cardio-metabolic disease prevention.
Ther Adv Cardiovasc Dis. 2023 Jan-Dec;17:17539447231177175. doi: 10.1177/17539447231177175.
7
Gut Microbiota and Cardiovascular Disease: Evidence on the Metabolic and Inflammatory Background of a Complex Relationship.
Int J Mol Sci. 2023 May 22;24(10):9087. doi: 10.3390/ijms24109087.
8
A Heart-Healthy Diet for Cardiovascular Disease Prevention: Where Are We Now?
Vasc Health Risk Manag. 2023 Apr 21;19:237-253. doi: 10.2147/VHRM.S379874. eCollection 2023.
9
Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3.
J Am Coll Cardiol. 2023 Apr 25;81(16):1633-1645. doi: 10.1016/j.jacc.2023.02.033.
10
Cardiometabolic health, diet and the gut microbiome: a meta-omics perspective.
Nat Med. 2023 Mar;29(3):551-561. doi: 10.1038/s41591-023-02260-4. Epub 2023 Mar 17.
Zotero 插件